Supriya Lifescience expands global footprint with Esketamine Hydrochloride approval, Atorvastatin patent filing

Published On 2024-12-11 04:30 GMT   |   Update On 2024-12-11 04:30 GMT
Advertisement

Mumbai: Supriya Lifescience Ltd. has acquired approval from Brazil's health authority, ANVISA (Agência Nacional de Vigilância Sanitária), for Esketamine Hydrochloride This approval will help the company to grow its product range in Brazil and the rest of LATAM.

 Supriya Lifescience Ltd. achieved two significant milestones, strengthening its position in international markets. It is the first firm in Brazil to have received regulatory permission for this highly specialised pharmaceutical, the Company claimed.

Esketamine hydrochloride is a vital drug to be used for treating mental illness.

"This approval will enable the company to provide state-of-the-art, high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing. Moreover, the business submitted a ground-breaking patent application for an enhanced, low-cost method of atorvastatin synthesis. This ground-breaking technique makes drugs more affordable for patients by increasing their efficacy while reducing production costs. Global healthcare relies heavily on atorvastatin, a key treatment for controlling cholesterol and preventing cardiovascular disease, and this achievement shows Supriya's dedication to drug cost and raising accessibility," the Company stated in a release.

Dr. Satish Wagh, Executive Chairman and Whole Time Director, Supriya Lifescience Ltd. stated, "Our commitment to transforming pharmaceutical manufacturing while maintaining affordability is demonstrated by our invention in the synthesis of atorvastatin. Our global presence is strengthened by the CADIFA approval, which also allows us to introduce cutting-edge therapies like Esketamine Hydrochloride in important foreign countries, starting with Brazil."

Supriya Lifescience Ltd., a producer of active pharmaceutical ingredients, was founded in 1987. The cutting-edge facility has certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. The company is headquartered in Mumbai, India, and its facility is located in Khed, District Ratnagiri. Its globally compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA) are supported by robust R&D, eight active CEPs, and fourteen active USDMFs. EHS requirements and ethical principles guide our core business. The company's primary focus is to build intermediates and APIs for innovators and generic firms. The company also exclusively collaborate with partners in the capacity of CMOs.


Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News